申请人:Janssen Pharmaceutica N.V.
公开号:US20150183735A1
公开(公告)日:2015-07-02
The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein
n is 1 or 2;
L represents a C
1-3
alkyl linker optionally substituted with one or two substituents selected from C
1-4
alkyl, C
1-3
alkyloxy-C
1-4
alkyl-, hydroxy-C
1-4
alkyl, hydroxy, C
1-3
alkyloxy- or phenyl-C
1-4
alkyl;
M represents a direct bond or a C
1-3
alkyl linker optionally substituted with one or two substituents selected from hydroxy, C
1-4
alkyl or C
1-4
alkyloxy;
R
1
and R
2
each independently represent hydrogen, halo, cyano, hydroxy, C
1-4
alkyl optionally substituted with halo,
C
1-4
alkyloxy- optionally substituted with one or where possible two or three substituents selected from hydroxy, Ar
1
and halo;
or R
1
and R
2
taken together with the phenyl ring to which they are attached form naphtyl or 1,3-benzodioxolyl, wherein said naphtyl or 1,3-benzodioxolyl are optionally substituted with halo;
R
3
represents hydrogen, halo, C
1-4
alkyl, C
1-4
alkyloxy-, cyano or hydroxy;
R
4
represents hydrogen, halo, C
1-4
alkyl, C
1-4
alkyloxy-, cyano or hydroxy;
R
5
represents hydrogen, C
1-4
alkyl or Ar
2
—C
1-4
alky-;
R
6
represents hydrogen, halo, C
1-4
alkyl or C
1-4
alkyoxy-;
Ar
1
and Ar
2
each independently represent phenyl or naphtyl wherein said phenyl and naphtyl are optionally substituted with C
1-4
alkyl, C
1-4
alkyloxy-, or phenyl-C
1-4
alkyl;
for use as a medicine.